GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » Cyclically Adjusted Book per Share

Akebia Therapeutics (STU:AX9) Cyclically Adjusted Book per Share : €2.86 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Akebia Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was €-0.120. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.86 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Akebia Therapeutics's average Cyclically Adjusted Book Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-26), Akebia Therapeutics's current stock price is €1.008. Akebia Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €2.86. Akebia Therapeutics's Cyclically Adjusted PB Ratio of today is 0.35.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Akebia Therapeutics was 0.66. The lowest was 0.09. And the median was 0.35.


Akebia Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Akebia Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Cyclically Adjusted Book per Share Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2.55 3.04

Akebia Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.82 2.85 2.81 3.04 2.86

Competitive Comparison of Akebia Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Akebia Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted PB Ratio falls into.



Akebia Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akebia Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.12/131.7762*131.7762
=-0.120

Current CPI (Mar. 2024) = 131.7762.

Akebia Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.415 100.560 5.786
201409 4.343 100.428 5.699
201412 4.144 99.070 5.512
201503 4.270 99.621 5.648
201506 4.620 100.684 6.047
201509 4.288 100.392 5.629
201512 3.922 99.792 5.179
201603 3.970 100.470 5.207
201606 3.121 101.688 4.044
201609 2.346 101.861 3.035
201612 1.672 101.863 2.163
201703 0.737 102.862 0.944
201706 1.194 103.349 1.522
201709 1.774 104.136 2.245
201712 2.175 104.011 2.756
201803 2.811 105.290 3.518
201806 2.496 106.317 3.094
201809 2.141 106.507 2.649
201812 4.782 105.998 5.945
201903 4.280 107.251 5.259
201906 3.869 108.070 4.718
201909 3.572 108.329 4.345
201912 2.920 108.420 3.549
202003 2.754 108.902 3.332
202006 2.297 108.767 2.783
202009 1.883 109.815 2.260
202012 1.375 109.897 1.649
202103 1.133 111.754 1.336
202106 0.854 114.631 0.982
202109 0.668 115.734 0.761
202112 0.370 117.630 0.414
202203 0.129 121.301 0.140
202206 0.321 125.017 0.338
202209 0.076 125.227 0.080
202212 0.027 125.222 0.028
202303 -0.072 127.348 -0.075
202306 -0.132 128.729 -0.135
202309 -0.196 129.860 -0.199
202312 -0.144 129.419 -0.147
202403 -0.120 131.776 -0.120

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Akebia Therapeutics  (STU:AX9) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Akebia Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.008/2.86
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Akebia Therapeutics was 0.66. The lowest was 0.09. And the median was 0.35.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Akebia Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics (STU:AX9) Business Description

Industry
Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines